CYPHERPUNK TECHNOLOGIES INC. Proceeds from Warrant Exercises
CYPHERPUNK TECHNOLOGIES INC. (CYPH) reported Proceeds from Warrant Exercises of $41.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromWarrantExercises · last filed 2026-03-16
- CYPHERPUNK TECHNOLOGIES INC. proceeds from warrant exercises for the quarter ending 2021-12-31 was $939.00K.
- CYPHERPUNK TECHNOLOGIES INC. proceeds from warrant exercises for the quarter ending 2021-09-30 was $40.00K.
- CYPHERPUNK TECHNOLOGIES INC. proceeds from warrant exercises for the quarter ending 2021-06-30 was $0.00, a 100.00% decline year-over-year.
- CYPHERPUNK TECHNOLOGIES INC. proceeds from warrant exercises for the quarter ending 2021-03-31 was $14.00K, a 89.06% decline year-over-year.
- CYPHERPUNK TECHNOLOGIES INC. proceeds from warrant exercises for fiscal 2024 was $41.00K.
- CYPHERPUNK TECHNOLOGIES INC. proceeds from warrant exercises for fiscal 2021 was $993.00K, a 185.34% increase from fiscal 2020.
- CYPHERPUNK TECHNOLOGIES INC. proceeds from warrant exercises for fiscal 2020 was $348.00K.
- CYPHERPUNK TECHNOLOGIES INC. proceeds from warrant exercises for fiscal 2018 was $1.22M.
| Period end | Proceeds from Warrant Exercises 3 month | Proceeds from Warrant Exercises 6 month | Proceeds from Warrant Exercises 9 month | Proceeds from Warrant Exercises 12 month |
|---|---|---|---|---|
| 2024-12-31 | $41.00K 10-K · filed 2026-03-16 | |||
| 2021-12-31 | $939.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | $979.00K derived: sum of 2 quarters · filed 2023-03-24 | $979.00K derived: sum of 3 quarters · filed 2023-03-24 | $993.00K 10-K · filed 2023-03-24 |
| 2021-09-30 | $40.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $40.00K derived: sum of 2 quarters · filed 2022-11-14 | $54.00K 10-Q · filed 2022-11-14 | $54.00K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $14.00K 10-Q · filed 2022-08-12 | $14.00K derived: sum of 3 quarters · filed 2022-08-12 | $14.00K derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | $14.00K 10-Q · filed 2022-05-13 | $14.00K derived: sum of 2 quarters · filed 2022-05-13 | $14.00K derived: sum of 3 quarters · filed 2022-05-13 | $234.00K derived: sum of 4 quarters · filed 2022-05-13 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $0.00 derived: sum of 2 quarters · filed 2022-03-11 | $220.00K derived: sum of 3 quarters · filed 2022-03-11 | $348.00K 10-K · filed 2022-03-11 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $220.00K derived: sum of 2 quarters · filed 2021-11-12 | $348.00K 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $220.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | $348.00K 10-Q · filed 2021-08-13 | ||
| 2020-03-31 | $128.00K 10-Q · filed 2021-05-14 | |||
| 2018-12-31 | $1.20M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $2.42M derived: sum of 2 quarters · filed 2020-03-16 | $3.64M derived: sum of 3 quarters · filed 2020-03-16 | $1.22M 10-K · filed 2020-03-16 |
| 2018-09-30 | $1.22M 10-Q · filed 2018-11-09 | $2.43M derived: sum of 2 quarters · filed 2018-11-09 | $14.00K 10-Q · filed 2018-11-09 | |
| 2018-06-30 | $1.22M 10-Q · filed 2018-08-08 | $1.22M 10-Q · filed 2018-08-08 | ||
| 2017-09-30 | $20.00K 10-Q · filed 2018-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |